Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Sanofi
Michel Attal; Paul G Richardson; S Vincent Rajkumar; Jesus San-Miguel; Meral Beksac; Ivan Spicka; Xavier Leleu; Fredrik Schjesvold; Philippe Moreau; Meletios A Dimopoulos; Jeffrey Shang-Yi Huang; Jiri Minarik; Michele Cavo; H Miles Prince; Sandrine Macé; Kathryn P Corzo; Frank Campana; Solenn Le-Guennec; Franck Dubin; Kenneth C Anderson